TERM ID="NYU_TERM_1" STRING="ADC brentuximab vedotin" FREQUENCY=1 START=1126 END=1149 LEMMA="ADC BRENTUXIMAB VEDOTIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="ADC technology" FREQUENCY=2 START=188 END=202 LEMMA="ADC TECHNOLOGY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_3" STRING="ADC technology" FREQUENCY=2 START=582 END=596 LEMMA="ADC TECHNOLOGY" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_4" STRING="ADCs" FREQUENCY=4 START=99 END=103 LEMMA="ANTIBODY DRUG CONJUGATES" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_5" STRING="ADCs" FREQUENCY=4 START=657 END=661 LEMMA="ANTIBODY DRUG CONJUGATES" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_6" STRING="ADCs" FREQUENCY=4 START=814 END=818 LEMMA="ANTIBODY DRUG CONJUGATES" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_7" STRING="ADCs" FREQUENCY=4 START=905 END=909 LEMMA="ANTIBODY DRUG CONJUGATES" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_8" STRING="Antibody-drug" FREQUENCY=2 START=0 END=13 LEMMA="ANTIBODY-DRUG" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_9" STRING="Antibody-drug" FREQUENCY=2 START=73 END=86 LEMMA="ANTIBODY-DRUG" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_10" STRING="Antibody-drug conjugates" FREQUENCY=1 START=73 END=97 LEMMA="ANTIBODY-DRUG CONJUGATE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="CD22" FREQUENCY=1 START=991 END=995 LEMMA="CD22" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="CD30" FREQUENCY=1 START=1001 END=1005 LEMMA="CD30" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="Drug Administration" FREQUENCY=1 START=1191 END=1210 LEMMA="DRUG ADMINISTRATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_14" STRING="Hodgkin lymphoma" FREQUENCY=1 START=1246 END=1262 LEMMA="HODGKIN LYMPHOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_15" STRING="Other ADCs" FREQUENCY=1 START=1508 END=1518 LEMMA="OTHER ADC" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="ability" FREQUENCY=1 START=530 END=537 LEMMA="ABILITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="antibody" FREQUENCY=3 START=240 END=248 LEMMA="ANTIBODY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_18" STRING="antibody" FREQUENCY=3 START=306 END=314 LEMMA="ANTIBODY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_19" STRING="antibody" FREQUENCY=3 START=341 END=349 LEMMA="ANTIBODY" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_20" STRING="antibody specificity" FREQUENCY=1 START=140 END=160 LEMMA="ANTIBODY SPECIFICITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="antigen" FREQUENCY=1 START=227 END=234 LEMMA="ANTIGEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_22" STRING="antigens" FREQUENCY=1 START=951 END=959 LEMMA="ANTIGEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_23" STRING="autologous stem cell transplant" FREQUENCY=1 START=1280 END=1311 LEMMA="AUTOLOGOUS STEM CELL TRANSPLANT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="clinical trials" FREQUENCY=1 START=1522 END=1537 LEMMA="CLINICAL TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="clinical trials for hematologic disorders" FREQUENCY=1 START=1522 END=1563 LEMMA="HEMATOLOGIC DISORDER CLINICAL TRIAL" LEMMA_FREQUENCY=1 HEAD_TERM="clinical trials" HEAD_LEMMA="CLINICAL TRIAL"
TERM ID="NYU_TERM_26" STRING="cytotoxic agent" FREQUENCY=2 START=362 END=377 LEMMA="CYTOTOXIC AGENT" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_27" STRING="cytotoxic agent" FREQUENCY=2 START=448 END=463 LEMMA="CYTOTOXIC AGENT" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_28" STRING="cytotoxic agents" FREQUENCY=2 START=857 END=873 LEMMA="CYTOTOXIC AGENT" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_29" STRING="cytotoxic agents" FREQUENCY=2 START=1050 END=1066 LEMMA="CYTOTOXIC AGENT" LEMMA_FREQUENCY=4
TERM ID="NYU_TERM_30" STRING="cytotoxic chemotherapy" FREQUENCY=1 START=113 END=135 LEMMA="CYTOTOXIC CHEMOTHERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="enabling delivery" FREQUENCY=1 START=468 END=485 LEMMA="ENABLING DELIVERY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_32" STRING="gemtuzumab ozogamicin" FREQUENCY=1 START=1608 END=1629 LEMMA="GEMTUZUMAB OZOGAMICIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_33" STRING="hematologic disorders" FREQUENCY=2 START=51 END=72 LEMMA="HEMATOLOGIC DISORDER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_34" STRING="hematologic disorders" FREQUENCY=2 START=1542 END=1563 LEMMA="HEMATOLOGIC DISORDER" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_35" STRING="including CD19" FREQUENCY=1 START=975 END=989 LEMMA="INCLUDING CD19" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="including calicheamicin" FREQUENCY=1 START=1068 END=1091 LEMMA="INCLUDING CALICHEAMICIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_37" STRING="inotuzumab ozogamicin" FREQUENCY=1 START=1572 END=1593 LEMMA="INOTUZUMAB OZOGAMICIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="linker" FREQUENCY=1 START=269 END=275 LEMMA="LINKER" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_39" STRING="linkers" FREQUENCY=2 START=667 END=674 LEMMA="LINKER" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_40" STRING="linkers" FREQUENCY=2 START=824 END=831 LEMMA="LINKER" LEMMA_FREQUENCY=3
TERM ID="NYU_TERM_41" STRING="maytansinoid derivatives" FREQUENCY=1 START=1096 END=1120 LEMMA="MAYTANSINOID DERIVATIVE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_42" STRING="multiagent chemotherapy regimen" FREQUENCY=1 START=1475 END=1506 LEMMA="MULTIAGENT CHEMOTHERAPY REGIMEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_43" STRING="multiagent chemotherapy regimens" FREQUENCY=1 START=1332 END=1364 LEMMA="MULTIAGENT CHEMOTHERAPY REGIMEN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_44" STRING="off-target toxicity" FREQUENCY=1 START=764 END=783 LEMMA="OFF-TARGET TOXICITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_45" STRING="receptors" FREQUENCY=1 START=964 END=973 LEMMA="RECEPTOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_46" STRING="side effect profile" FREQUENCY=1 START=421 END=440 LEMMA="SIDE EFFECT PROFILE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_47" STRING="side effect profile of the cytotoxic agent" FREQUENCY=1 START=421 END=463 LEMMA="CYTOTOXIC AGENT SIDE EFFECT PROFILE" LEMMA_FREQUENCY=1 HEAD_TERM="side effect profile" HEAD_LEMMA="SIDE EFFECT PROFILE"
TERM ID="NYU_TERM_48" STRING="side effects" FREQUENCY=1 START=568 END=580 LEMMA="SIDE EFFECT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_49" STRING="systemic anaplastic large cell lymphoma" FREQUENCY=1 START=1401 END=1440 LEMMA="SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_50" STRING="technology development" FREQUENCY=1 START=24 END=46 LEMMA="TECHNOLOGY DEVELOPMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_51" STRING="technology development for hematologic disorders" FREQUENCY=1 START=24 END=72 LEMMA="HEMATOLOGIC DISORDER TECHNOLOGY DEVELOPMENT" LEMMA_FREQUENCY=1 HEAD_TERM="technology development" HEAD_LEMMA="TECHNOLOGY DEVELOPMENT"
TERM ID="NYU_TERM_52" STRING="technology development for hematologic disorders Antibody-drug" FREQUENCY=1 START=24 END=86 LEMMA="ANTIBODY-DRUG HEMATOLOGIC DISORDER TECHNOLOGY DEVELOPMENT" LEMMA_FREQUENCY=1 HEAD_TERM="Antibody-drug" HEAD_LEMMA="ANTIBODY-DRUG"
TERM ID="NYU_TERM_53" STRING="tumor cell" FREQUENCY=1 START=385 END=395 LEMMA="TUMOR CELL" LEMMA_FREQUENCY=1
